Figure 8From: AIMAR survey on complex forms of bronchial asthma and COPD, their management and perception of critical issuesThe FDA recently cautioned against the sole use of LABAs in asthmatic patients, so as to avoid masking the symptom and a concomitant worsening of the disease. In your opinion, how “risky” is the sole use of a bronchodilator for a patient with mixed forms?Back to article page